It was a really pleasure to discuss our academic data on the efficacy and safety of Trastuzumab-Deruxtecan in HER2+ MBC old pts (>70yrs) at #ESMOBreast23 . Age should not be a criterion to descourage a so active treatment!
Do not miss our poster during today’s lunch break❗️
Stop by and discuss obesity and recurrence rates in HR+ postmenopausal breast cancer patients treated with AIs🔬
#ESMObreast23
ESMO - Eur. Oncology
#ESMOBreast23 Check out our poster showing that patients switching to ER-low phenotype from early to advanced BC esperience even poorer prognosis than those switching to pure TNBC.
We need to grant ER-low pts access to TNBC trials and treatment algorithms
Today's sessions with Ann Partridge MD, MPH were incredibly informative, and her presentation was particularly impressive when discussing biological peculiarities. Thank you, doctor.
#ESMOBreast23 Dana-Farber #YoungOncologists
Treatment algorithms in mBC👇
From the #ASCO23 and #ESMOBreast23 presentations
HR+/HER2- by Dr. Daniel Stover, MD, FASCO
HER2+ by Dr. Shanu Modi
OncoAlert
Dr. Otto Metzger (Otto Metzger) presenting at #ESMOBreast23 👉From SERMs to SERDs: Advances and challenges in the development of novel agents (focus on biomarkers) and moderating the educational session on targeted options for advanced luminal breast cancers.
1st #ESMOBreast23 ✅
Plenty of learning & opportunities for discussion.
Plus great presentations by my amazing colleagues & friends Mairi Lucas & Kate Murphy🇮🇪
We’ll be back!
ESMO - Eur. Oncology OncoAlert Precision Oncology Ireland RCSI_StAR MD CancerTrialsIreland 🌈 University College Dublin St Vincent's University Hospital (SVUH) UCC Cancer Trials Group
👏👏👏Outstanding lecture by Christine Desmedt at #ESMOBreast23 on translational BC research highlighting the importance of ctDNA and need for res on lobular BC
3,2,1 go...Our Pharmacy Service with Oncological Medical Service are represented in Berlin...new hypothesis are comming...when less could be more...specially in oral fixed doses TKI's... ESMO - Eur. Oncology GEDEFO S.E.F.H ISOPP SEOM #ESMOBreast23 cslide.ctimeetingtech.com/breast23hybrid…
Superb insights & advice at the #ESMOYOC session on international research opportunities & collaborations 🌎 ESMO - Eur. Oncology FabriceAndre Evandro de Azambuja, MD, PhD Nadia Harbeck, Kevin Punie Ana Tecic Vuger Rodrigo Sánchez-Bayona Cancer Research @UCC UCC Cancer Trials Group #ESMOBreast23
#ESMOBreast23
Conclusions from the excellent translational research highlights overview by Christine Desmedt👏 ESMO - Eur. Oncology OncoAlert #bcsm Lobular Breast Cancer Alliance KarenVanBaelen Hava Izci
I told swaggsheila she almost got a standing ovation!! ICYMI - here she is sharing her experience participating in the Destiny Breast-02 trial at #ESMOBreast23 .
#bcsm
When you find a #BRCA mutation on cancer tissue or ctDNA, always remember to evaluate the germline mutation status!
In #breastcancer :
gBRCA 👉 ESCAT IA
sBRCA 👉 ESCAT IIIA
#ESMOBreast23 ESMO - Eur. Oncology
Can we omit anthracyclins for TNBC early breast cancer? Meta analysis . Non inferior for recurrence but not for over all mortality. ESMO - Eur. Oncology #ESMOBreast23
We're excited to share more insights from #ESMOBreast23 !
A huge “Thank You” to the Top 10 Commenters from the conference for their valuable contributions to the #Oncology community. 🤩
#ESMOBreast23 #Oncology Conference #CancerResearch #CancerTherapy #CancerTreatment
Why atezo failed and pembrolizumab worked in TNBC ? Is pembro better drug than Atezo ? May be . ESMO - Eur. Oncology #ESMOBreast23
